NLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

ZURICH, SWITZERLAND / ACCESSWIRE / December 7, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery

Related Keywords

Switzerland ,Zurich ,Züsz ,Swiss ,Marianne Lambertson ,Nasdaq Hearings Panel The ,Exchange Commission ,European Medicines Agency ,Nasdaq Stock Market ,Drug Administration ,Nasdaq ,Pharmaceutics Ltd ,Listing Rule ,Nasdaq Listing Rule ,Nasdaq Staff ,Nasdaq Hearings Panel ,Nasdaq Capital ,Orphan Disease Designation ,Mazindol Controlled Release ,Orphan Drug Designations ,Pharmaceutics ,Nnounces ,Receipt ,Minimum ,Price ,Notification ,